ARTICLE | Clinical News
VIA-2291: Phase II started
January 14, 2008 8:00 AM UTC
Via began the double-blind, U.S. Phase II FDG-PET trial in about 50 patients following a heart attack to compare 100 mg of VIA-2291 given once daily vs. placebo for 24 weeks. ...